CARsgen Therapeutics Holdings Ltd
HKEX:2171
Net Margin
CARsgen Therapeutics Holdings Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
CARsgen Therapeutics Holdings Ltd
HKEX:2171
|
8.7B HKD |
-2 024%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
328.4B USD |
8%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
150.8B USD |
12%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
128.5B USD |
2%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126.9B USD |
-5%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
118.3B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
66B USD |
31%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
32.7B EUR |
38%
|
CARsgen Therapeutics Holdings Ltd
Glance View
CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on CARsgen Therapeutics Holdings Ltd's most recent financial statements, the company has Net Margin of -2 024.4%.
You don't have any saved screeners yet